- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- CLLS
- Stock Information
- Founded
- AOMR 2018
- CLLS 1999
- Country
- AOMR United States
- CLLS France
- Employees
- AOMR N/A
- CLLS N/A
- Industry
- AOMR Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- CLLS Health Care
- Exchange
- AOMR Nasdaq
- CLLS Nasdaq
- Market Cap
- AOMR 216.1M
- CLLS 240.2M
- IPO Year
- AOMR 2021
- CLLS 2007
- Fundamental
- Price
- AOMR $9.33
- CLLS $1.57
- Analyst Decision
- AOMR Buy
- CLLS Buy
- Analyst Count
- AOMR 6
- CLLS 3
- Target Price
- AOMR $12.10
- CLLS $7.00
- AVG Volume (30 Days)
- AOMR 98.2K
- CLLS 59.8K
- Earning Date
- AOMR 11-06-2024
- CLLS 11-04-2024
- Dividend Yield
- AOMR 13.93%
- CLLS N/A
- EPS Growth
- AOMR N/A
- CLLS N/A
- EPS
- AOMR 2.91
- CLLS N/A
- Revenue
- AOMR $94,441,000.00
- CLLS $36,042,000.00
- Revenue This Year
- AOMR N/A
- CLLS $271.02
- Revenue Next Year
- AOMR $31.91
- CLLS $33.48
- P/E Ratio
- AOMR $3.16
- CLLS N/A
- Revenue Growth
- AOMR 455.18
- CLLS 46.96
- 52 Week Low
- AOMR $8.88
- CLLS $1.53
- 52 Week High
- AOMR $13.32
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- AOMR 44.36
- CLLS 27.91
- Support Level
- AOMR $8.95
- CLLS $1.85
- Resistance Level
- AOMR $9.34
- CLLS $2.09
- Average True Range (ATR)
- AOMR 0.21
- CLLS 0.09
- MACD
- AOMR -0.02
- CLLS -0.04
- Stochastic Oscillator
- AOMR 37.57
- CLLS 0.00
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.